Clinical Trial Results:
A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy
Summary
|
|
EudraCT number |
2005-004094-25 |
Trial protocol |
CZ AT FI SK IE HU DE ES SE GB PT BE DK GR IT |
Global completion date |
08 Apr 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Oct 2016
|
First version publication date |
13 Oct 2016
|
Other versions |
|
Summary report(s) |
Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.